Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 464 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adolescent Cancer Clear all
Completed Phase 2 Interventional Results available

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

NCT01848457
View directory record Official record
Conditions
Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions
Pantoprazole, High-dose methotrexate infusion duration
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

NCT06139172
View directory record Official record
Conditions
Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple, Fragile X Syndrome, Angelman Syndrome, Rett Syndrome, Chromosome 15Q, Partial Deletion, Creatine Deficiency, X-linked
Interventions
Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
2 Years to 12 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

NCT06654466
View directory record Official record
Conditions
Hereditary Cancer Syndromes, Clinical Decision Support
Interventions
Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.
Device
Lead sponsor
Nest Genomics
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jun 25, 2026, 5:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Exercise and Pain in AYACS

NCT05562570
View directory record Official record
Conditions
AYA Cancer Survivors
Interventions
Physical activity intervention coupled with standard post-cancer directed treatment care, Standard post-cancer directed treatment care control
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 25, 2026, 5:49 PM EDT
Active, not recruiting Not applicable Interventional

ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer

NCT05792566
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Atomic app
Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
10 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

NCT04225676
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Resistance Training Program and Cardiovascular Exercise in Increasing Muscle Mass in Adolescent and Young Adult Stem Cell Transplant Survivors

NCT03672981
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Mila Blooms Intervention Study

NCT01473342
View directory record Official record
Conditions
Childhood Cancer
Interventions
Mila Blooms
Behavioral
Lead sponsor
Duke University
Other
Eligibility
12 Years to 19 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

NCT03266653
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jun 25, 2026, 5:49 PM EDT
Active, not recruiting No phase listed Observational

Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)

NCT02515383
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891
View directory record Official record
Conditions
High-Grade Glioma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Palo Alto, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Terminated No phase listed Observational

Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer

NCT00933088
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaires
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 19 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting No phase listed Observational

A Study of Questionnaires in Adolescents and Young Adults With Cancer

NCT07212166
View directory record Official record
Conditions
Adolescents and Young Adults With Cancer
Interventions
Patient-Reported Outcome Surveys, Spanish version of PRO-AYA and the cognitive interview
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

NCT04923126
View directory record Official record
Conditions
Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 24 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

NCT05958316
View directory record Official record
Conditions
Symptoms and Signs, Cancer, Childhood Cancer
Interventions
Computerized Symptom Capture Tool (C-SCAT) Intervention, Usual Care Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 29 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Kansas City, Missouri • Salt Lake City, Utah • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

NCT03932903
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
ADAPTS (ADherence Assessments and Personalized Timely Support).
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
14 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Smoking Cessation for Young Adult Pacific Islanders: Motivating Pacifika Against Cigarettes and Tobacco

NCT03238456
View directory record Official record
Conditions
Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Smoking, Smoking Cessation, Smoking, Cigarette
Interventions
Motivating Pacifika Against Cigarettes and Tobacco
Behavioral
Lead sponsor
Claremont Graduate University
Other
Eligibility
18 Years to 30 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Claremont, California • Fullerton, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

NCT01956669
View directory record Official record
Conditions
Solid Tumours
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
24
States / cities
Long Beach, California • Madera, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jun 25, 2026, 5:49 PM EDT
Recruiting Early Phase 1 Interventional

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

NCT03719105
View directory record Official record
Conditions
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Interventions
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 31 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jun 25, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

NCT04158739
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Flotetuzumab
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 25, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors

NCT02699996
View directory record Official record
Conditions
Cancer Survivor
Interventions
Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 29 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Jun 25, 2026, 5:49 PM EDT